SLC26A11

Across TCGA pan-cancer cohorts, SLC26A11 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC26A11 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SLC26A11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC26A11 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM and LUAD are the cancer types where SLC26A11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.737	0.960	.002	27	view →
LUAD	DFS	Median	All	1.000	0.272	.004	17	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC26A11–GBM (OS)

Open the GBM breakdown →